NVZMY Novozymes Earnings Miss: EPS Down 37.5% vs Estimates

Novozymes A/S (NVZMY) delivered a disappointing earnings report on May 5, 2026, missing analyst expectations on both earnings and revenue. The industrial enzyme and biotech company reported earnings per share of $0.51, falling 37.5% short of the $0.82 consensus estimate. Revenue came in at $1.31 billion, missing the $1.32 billion forecast by just under 1%. The miss marks a concerning trend for the specialty chemicals firm, which has struggled to meet profit expectations across recent quarters. Meyka AI rates NVZMY with a grade of B, reflecting mixed fundamentals amid execution challenges.

Earnings Miss Signals Profitability Pressure

Novozymes’ latest earnings report reveals significant profitability headwinds despite modest revenue performance. The company’s $0.51 EPS represents a sharp decline from analyst expectations, marking the third consecutive quarter of substantial earnings misses.

EPS Performance Deteriorates

The 37.5% EPS miss is the most severe shortfall in the past four quarters. Prior quarters showed similar struggles: February 2026 delivered $0.35 EPS versus $0.79 estimate, while August 2025 posted $0.046 against a $0.67 target. This pattern suggests operational challenges beyond temporary headwinds, pointing to margin compression or cost control issues within the business.

Revenue Barely Misses Target

Revenue of $1.31 billion fell just short of the $1.32 billion estimate by less than 1%. While the revenue miss is minimal, the disconnect between top-line performance and bottom-line results indicates deteriorating profitability. The company generated adequate sales but failed to convert them into expected earnings, a red flag for operational efficiency.

Quarterly Trend Shows Worsening Earnings Quality

Examining Novozymes’ earnings trajectory over the past year reveals a troubling pattern of declining profitability despite relatively stable revenues. The company has consistently underperformed on earnings while maintaining near-target revenue levels.

Consistent EPS Shortfalls

Over four consecutive quarters, NVZMY has missed EPS estimates by significant margins. The current quarter’s $0.51 actual versus $0.82 estimate continues this trend. February 2026 showed $0.35 actual versus $0.79 estimate, an even larger miss. August 2025 delivered $0.046 actual versus $0.67 estimate, the worst performance. This consistent underperformance suggests structural profitability issues rather than one-time charges.

Revenue Stability Masks Profit Decline

While revenue estimates have remained relatively consistent around $1.2-1.3 billion, actual results show volatility. Current quarter revenue of $1.31 billion is solid, but prior quarters showed significant revenue misses. The gap between revenue and earnings performance indicates margin compression, likely from higher costs or operational inefficiencies affecting the specialty chemicals business.

Stock Market Reaction and Valuation Concerns

The market responded negatively to Novozymes’ earnings miss, with the stock declining following the announcement. Current trading reflects investor disappointment over persistent profitability challenges and uncertain near-term recovery prospects.

Post-Earnings Price Action

NVZMY traded at $61.27, down 1.68% from the previous close of $62.32. The decline reflects typical market reaction to earnings misses, though the relatively modest drop suggests investors may have partially priced in weak results. The stock remains well below its 52-week high of $75.99, indicating broader weakness beyond just this earnings report.

Valuation Metrics Raise Red Flags

The company’s P/E ratio of 40.7 appears elevated given the earnings misses and profitability challenges. With a market cap of $28.46 billion and consistent EPS underperformance, the valuation leaves little room for disappointment. The stock trades at 1.98x book value, suggesting investors are pricing in future recovery that may not materialize given current execution issues.

Meyka AI Grade and Forward Outlook

Meyka AI rates Novozymes with a grade of B, reflecting mixed fundamentals and execution challenges. The rating suggests the company has solid underlying assets but faces near-term headwinds that warrant caution from investors.

What the B Grade Means

The B rating indicates Novozymes possesses reasonable business fundamentals but is hampered by profitability issues and valuation concerns. The company operates in growing biotech and specialty chemicals markets, providing long-term tailwinds. However, consistent earnings misses and margin compression suggest management is struggling to execute effectively in the current environment.

Key Metrics to Monitor

Investors should watch operating margins, which appear compressed based on the revenue-to-earnings disconnect. The company’s dividend yield of 1.65% provides modest income, but sustainability depends on improved earnings. Free cash flow generation remains important; the company generated $7.56 per share in free cash flow, providing some financial flexibility. Management guidance on cost reduction initiatives and margin recovery will be critical for future stock performance.

Final Thoughts

Novozymes A/S missed earnings expectations significantly in Q1 2026, with EPS falling 37.5% short of estimates at $0.51 versus $0.82. Revenue barely missed at $1.31 billion, but the larger concern is the persistent profitability gap evident across four consecutive quarters. The stock declined 1.68% post-earnings, trading at $61.27 with a concerning P/E ratio of 40.7. Meyka AI’s B grade reflects solid fundamentals undermined by execution challenges. Investors should demand clarity on cost management and margin recovery before adding positions, as the current valuation offers limited margin of safety given ongoing earnings misses.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.